Tekla Life Sciences Investors Paid Distribution
On September 30, 2020, Tekla Life Sciences Investors announced a distribution of $0.41 per share, primarily sourced from net realized long-term capital gains. The fund's total net assets under management are approximately $3.1 billion. As of July 31, 2020, the average annual return at NAV was 2.16%, with a cumulative total return of 32.41% for the fiscal year. The current distribution's annualized rate is 8.01% of NAV. The fund's performance is subject to changes based on future realized gains and losses.
- Distribution of $0.41 per share, primarily from long-term capital gains.
- Cumulative total return at NAV reached 32.41% for the fiscal year.
- Annualized current distribution rate at 8.01% of NAV.
- No net investment income or short-term capital gains reported.
- Potential for distribution changes based on investment performance.
BOSTON--(BUSINESS WIRE)--On September 30, 2020, Tekla Life Sciences Investors paid a distribution of
The following table sets forth the estimated amounts of the current distribution, paid on September 30, 2020, and the cumulative distributions paid this fiscal year-to-date from the following sources: net investment income, net realized short-term capital gains, net realized long-term capital gains and return of capital or other capital source.
|
Current
|
Percentage Breakdown of
|
Total Cumulative
|
Percentage Breakdown of
|
||||
Net Investment Income |
|
|
|
|
||||
Net Realized ST Cap Gains |
|
|
|
|
||||
Net Realized LT Cap Gains |
|
|
|
|
||||
Return of Capital or Other Capital Source |
|
|
|
|
||||
TOTAL (per common share): |
|
|
|
|
The table below includes information relating to the Fund’s performance based on its NAV for certain periods.
Average annual return at NAV for the period from July 31, 2015 through July 31, 2020 |
|
|
Annualized current distribution rate expressed as percentage of NAV as of July 31, 2020 |
|
|
Cumulative total return at NAV for the fiscal year, through July 31, 20202 |
|
|
Cumulative fiscal year-to-date distribution rate expressed as a percentage of NAV as of July 31, 20201 |
|
You should not draw any conclusions about the Fund’s investment performance from the amount of this distribution or from the terms of the Fund’s managed distribution policy.
The amounts and sources of distributions reported in this press release are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.
Tekla Life Sciences Investors (NYSE: HQL) is a closed-end fund that invests in companies in the healthcare industry.
Tekla Capital Management LLC, the Fund’s investment adviser, is a Boston, MA based healthcare-focused investment manager with approximately
Destra Capital Investments is the Fund’s marketing and investor support services agent. Please contact Destra Capital Investments at HQL@destracapital.com or call (877) 855-3434 if you have any questions regarding HQL.
1 The Fund’s current fiscal year began on October 1, 2019.
2 Cumulative total return at NAV is the percentage change in the Fund’s NAV and includes all distributions and assumes the reinvestment of those distributions for the period of September 30, 2019 through July 31, 2020.
